Phase II data in NSCLC with bemcentinib/KEYTRUDA combination: First stage of trial in previously treated patients reported 40% ORR and ca. 6 months median PFS in AXL positive patients, stage 2 actively enrolling patients Additional NSCLC data: Bemcentinib/TARCEVA phase II combination trial in first line EGFRm patients reported that median PFS has surpassed that of TARCEVA monotherapy, … Read more
Late breaking abstract at SITC: Analysis of first stage of phase II trial with selective AXL inhibitor bemcentinib + KEYTRUDA in previously treated advanced NSCLC patients Median progression-free-survival (mPFS) of 5.9 months in AXL positive vs 3.3 months in AXL negative patients (~80% improvement) Predominantly PD-L1 negative or weak-positive patient population Bergen, Norway, 6 November … Read more
Bergen, Norway, 6 November 2018 – BerGenBio ASA (OSE:BGBIO) will announce its results for the third quarter 2018 on Tuesday, 13 November 2018. A presentation by BerGenBio’s senior management team will take place at 10 am CET at: Hotel ContinentalStortingsgaten 24/260117 Oslo The presentation will webcast live and the link will be available at www.bergenbio.com … Read more
Combination of selective AXL inhibitor bemcentinib and KEYTRUDA® featured in late breaking abstract at leading IO conference SITC Analysis comprises stage 1 (n=24) in PhII trial in 2L advanced NSCLC Stage 2 open and enrolling Bergen, Norway, 2 November 2018 – BerGenBio ASA (OSE:BGBIO) announces that the analysis of the first stage of its Phase II clinical … Read more
Biomarker predicts clinical benefit rate of 70% and overall response rate of 40% in second line NSCLC. Melanoma combination study reports safety and efficacy. Bergen, Norway, 22 October 2018 – BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators have presented interim clinical and biomarker data from BerGenBio’s Phase II clinical programme with bemcentinib (BGB324), a … Read more
Bergen, Norway, 9 October 2018 – BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators will present interim clinical and biomarker data from its Phase II clinical programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor at the ESMO 2018 Congress in Munich (19 – 23 October 2018). Pre-clinical data on the role of … Read more
Bergen, Norway, 5 October 2018- BerGenBio ASA (OSE: BGBIO) announces that the first patient has been dosed in the second stage of the phase II trial (BGBC008) evaluating the Company’s selective AXL inhibitor bemcentinib in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with previously treated advanced adenocarcinoma of the lung (non-small cell lung cancer, NSCLC) … Read more
Overall response rate of 40% with the bemcentinib/KEYTRUDA combination observed in AXL-positive, previously treated NSCLC patients, including PD-L1 negative patients who are not expected to benefit from KEYTRUDA monotherapyMedian PFS of patients receiving the bemcentinib/TARCEVA combination in first line has surpassed that of TARCEVA monotherapyEncouraging efficacy reported for bemcentinib in combination with docetaxel chemotherapy in … Read more
Bergen, Norway, 5 September 2018 – BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators will present interim clinical data from its Phase II clinical development programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, in non-small cell lung cancer (NSCLC) at the 19th World Conference on Lung Cancer (WCLC) in Toronto (23 … Read more
Bergen, Norway, August 30th, 2018 – BerGenBio ASA (OSE:BGBIO), announces that Richard Godfrey, CEO of BerGenBio, is scheduled to present an overview of the Company’s business and ongoing phase II clinical development programme with its first-in-class selective AXL inhibitor bemcentinib at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.